Literature DB >> 10764622

Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells.

E Tomasello1, M Bléry, F Vély, E Vivier.   

Abstract

Despite the absence of antigen-specific receptors at their surface, NK cells can selectively eliminate virus-infected cells, tumor cells and allogenic cells. A dynamic and precisely coordinated balance between activating and inhibitory receptors governs NK cell activation programs. Multiple activating and inhibitory NK cell surface molecules have been described, a group of them acting as receptors for MHC class I molecules. In spite of their heterogeneity, activating NK cell receptors present remarkable structural and functional homologies with T cell- and B cell-antigen receptors. Inhibitory NK cell receptors operate at early stages of activating cascades by recruiting protein tyrosine phosphatases via intra- cytoplasmic motifs (ITIM), a strategy which is widely conserved in hematopoietic and non-hematopoietic cells. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764622     DOI: 10.1006/smim.2000.0216

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  27 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.

Authors:  Agueda Martínez-Barriocanal; Emma Comas-Casellas; Simo Schwartz; Margarita Martín; Joan Sayós
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

Review 3.  Natural killer cells: integrating diversity with function.

Authors:  Kuldeep Cheent; Salim I Khakoo
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

4.  Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D.

Authors:  Costin Tomescu; Domenico Mavilio; Luis J Montaner
Journal:  AIDS       Date:  2015-09-10       Impact factor: 4.177

5.  Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages.

Authors:  Serge Nataf; Adrienne Anginot; Carine Vuaillat; Luc Malaval; Nassima Fodil; Emmanuel Chereul; Jean-Baptiste Langlois; Christiane Dumontel; Gaelle Cavillon; Christian Confavreux; Marlène Mazzorana; Laurence Vico; Marie-Franaçoise Belin; Eric Vivier; Elena Tomasello; Pierre Jurdic
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

6.  IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.

Authors:  Costin Tomescu; Pablo Tebas; Luis J Montaner
Journal:  AIDS       Date:  2017-03-13       Impact factor: 4.177

7.  Identification of the mouse killer immunoglobulin-like receptor-like (Kirl) gene family mapping to chromosome X.

Authors:  Alice Y Welch; Masanori Kasahara; Lisa M Spain
Journal:  Immunogenetics       Date:  2003-02-04       Impact factor: 2.846

8.  Variation in the ligand binding domains of the CD94/NKG2 family of receptors in the squirrel monkey.

Authors:  Michelle L LaBonte; Joanne Russo; Stephanie Freitas; Dawn Keighley
Journal:  Immunogenetics       Date:  2007-09-25       Impact factor: 2.846

9.  The chicken immunoregulatory receptor families SIRP, TREM, and CMRF35/CD300L.

Authors:  Birgit C Viertlboeck; Ramona Schmitt; Thomas W Göbel
Journal:  Immunogenetics       Date:  2006-02-22       Impact factor: 2.846

10.  The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients.

Authors:  Natalie Eaton-Fitch; Hélène Cabanas; Stanley du Preez; Donald Staines; Sonya Marshall-Gradisnik
Journal:  J Transl Med       Date:  2021-07-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.